

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM828248

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Sorrento Therapeutics, Inc.		07/28/2023	Corporation: DELAWARE
Scintilla Pharmaceuticals, Inc.		07/28/2023	Corporation: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Scilex Holding Company		
<b>Street Address:</b>	960 San Antonio Road		
<b>City:</b>	Palo Alto		
<b>State/Country:</b>	CALIFORNIA		
<b>Postal Code:</b>	94303		
<b>Entity Type:</b>	Corporation: DELAWARE		
<b>PROPERTY NUMBERS Total: 7</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	5429288	DOSECONNECT	
<b>Registration Number:</b>	5449373	DOSECONNECT	
<b>Registration Number:</b>	5459332	DOSEDISC	
<b>Registration Number:</b>	5448790	SOFUSA	
<b>Registration Number:</b>	5428688	SOFUSA	
<b>Registration Number:</b>	5800560	SORRENTO	
<b>Registration Number:</b>	5800561	SORRENTO	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	714.668.6200		
<b>Email:</b>	johnkline@paulhastings.com		
<b>Correspondent Name:</b>	John Kline		
<b>Address Line 1:</b>	695 Town Center Drive		
<b>Address Line 2:</b>	Seventeenth Floor		
<b>Address Line 4:</b>	Costa Mesa, CALIFORNIA 92626		
<b>NAME OF SUBMITTER:</b>	John Kline		
<b>SIGNATURE:</b>	/s/ John Kline		

OP \$190.00 5429288

**DATE SIGNED:**

07/31/2023

**Total Attachments: 20**

source=Sorrento - IP Security Agreement (Subordinated) (Executed)(143900764.1)#page1.tif  
source=Sorrento - IP Security Agreement (Subordinated) (Executed)(143900764.1)#page2.tif  
source=Sorrento - IP Security Agreement (Subordinated) (Executed)(143900764.1)#page3.tif  
source=Sorrento - IP Security Agreement (Subordinated) (Executed)(143900764.1)#page4.tif  
source=Sorrento - IP Security Agreement (Subordinated) (Executed)(143900764.1)#page5.tif  
source=Sorrento - IP Security Agreement (Subordinated) (Executed)(143900764.1)#page6.tif  
source=Sorrento - IP Security Agreement (Subordinated) (Executed)(143900764.1)#page7.tif  
source=Sorrento - IP Security Agreement (Subordinated) (Executed)(143900764.1)#page8.tif  
source=Sorrento - IP Security Agreement (Subordinated) (Executed)(143900764.1)#page9.tif  
source=Sorrento - IP Security Agreement (Subordinated) (Executed)(143900764.1)#page10.tif  
source=Sorrento - IP Security Agreement (Subordinated) (Executed)(143900764.1)#page11.tif  
source=Sorrento - IP Security Agreement (Subordinated) (Executed)(143900764.1)#page12.tif  
source=Sorrento - IP Security Agreement (Subordinated) (Executed)(143900764.1)#page13.tif  
source=Sorrento - IP Security Agreement (Subordinated) (Executed)(143900764.1)#page14.tif  
source=Sorrento - IP Security Agreement (Subordinated) (Executed)(143900764.1)#page15.tif  
source=Sorrento - IP Security Agreement (Subordinated) (Executed)(143900764.1)#page16.tif  
source=Sorrento - IP Security Agreement (Subordinated) (Executed)(143900764.1)#page17.tif  
source=Sorrento - IP Security Agreement (Subordinated) (Executed)(143900764.1)#page18.tif  
source=Sorrento - IP Security Agreement (Subordinated) (Executed)(143900764.1)#page19.tif  
source=Sorrento - IP Security Agreement (Subordinated) (Executed)(143900764.1)#page20.tif

## INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement (“Agreement”) is entered into as of July 28, 2023, by and between **SCILEX HOLDING COMPANY**, a Delaware corporation, (the “Lender”), **SORRENTO THERAPEUTICS, INC.**, a Delaware corporation (“Sorrento”) and **SCINTILLA PHARMACEUTICALS, INC.**, a Delaware corporation (together with Sorrento, each a “Grantor” and collectively, the “Grantors”).

### RECITALS

A. Lender has agreed to make certain advances of money and to extend certain financial accommodation to the Grantors (the “Loans”) in the amounts and manner set forth in that certain Junior Secured, Super-Priority Debtor-in-Possession Loan and Security Agreement dated as of July 28, 2023 (as the same may be amended, modified or supplemented from time to time, collectively, the “Loan Agreement”); capitalized terms used herein are used as defined in the Loan Agreement).

B. Lender agreed to enter into Loan Agreement and provide the financing thereunder only upon the condition, among others, that each Grantor (i) grant a junior lien on and security interest in all intellectual property owned by such Grantor and (ii) execute an intellectual property security agreement to be recorded, as applicable, in the United States Patent and Trademark Office and the United States Copyright Office for purposes of providing notice of the security interest granted pursuant to the Loan Agreement with respect to United States issued patents and patent applications, registered trademarks and trademark applications, and registered copyrights included in the Collateral.

C. Pursuant to the terms of the Loan Agreement, each Grantor has granted to Lender, a junior lien and security interest in all of such Grantor’s right, title and interest in the Intellectual Property Collateral.

NOW, THEREFORE, in consideration of the premises and of the mutual covenants and agreements contained herein, the parties hereto hereby agree as follows:

### AGREEMENT

1. Grant of Security Interest. Subject to the terms and conditions of the DIP Orders, to secure the payment and performance of the Obligations, each Grantor hereby grants, pledges and assigns to the Lender the following:

- (a) Pursuant to Section 364(c)(2) of the Bankruptcy Code, valid, binding, continuing, enforceable, non-avoidable automatically and fully perfected first priority senior liens and security interests in (i) the United States patents and patent applications of such Grantor set forth on Exhibit A attached hereto, (ii) the United States registered trademarks and trademark applications of such Grantor set forth on Exhibit B attached hereto, together with the goodwill of the business of such Grantor connected with and symbolized by such trademarks (iii) the United States registered copyrights set forth on Exhibit C attached hereto, and (iv) the right to sue or otherwise recover for past, present and future infringements, dilutions and other violations of any of the foregoing, (the “Intellectual Property Collateral”), subject only to (x) the Priming Obligations, (y) the Carve Out and (z) the Permitted Liens so long as such liens were validly perfected as of the Petition Date (or were properly perfected subsequent to the Petition Date to the extent

permitted by section 546(b) of the Bankruptcy Code); and

- (b) Pursuant to Section 364(c)(3) of the Bankruptcy Code, valid, binding, continuing, enforceable, non-avoidable automatically and fully perfected junior liens on and security interests in all Intellectual Property Collateral (other than as set forth in clause (a) above).

2. Exclusions. Notwithstanding anything to the contrary in Section 1, no lien or security interest is granted in, and the Intellectual Property Collateral excludes, all Excluded Assets and any “intent-to-use” trademark application unless and until a “statement of use” or an “amendment to allege use” has been filed with, and accepted by, the United States Patent and Trademark Office pursuant to Section 1(c) or Section 1(d) of the Lanham Act (15 U.S.C. §1051, et seq.).

3. Recordation. Each Grantor authorizes the Commissioner for Patents, the Commissioner for Trademarks and the Register of Copyrights to record and register this Agreement upon request by Lender.

4. Loan Documents. This Agreement has been entered into pursuant to and in conjunction with the Loan Agreement, which is hereby incorporated by reference. The provisions of the Loan Agreement shall supersede and control over any conflicting or inconsistent provision herein. The rights and remedies of Lender, with respect to the Intellectual Property Collateral are as provided by the Loan Agreement and related documents, and nothing in this Agreement shall be deemed to limit such rights and remedies.

5. Counterparts; Electronic Execution. This Agreement may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, shall be deemed to be an original, and all of which, when taken together, shall constitute but one and the same Agreement. Delivery of an executed counterpart of this Agreement by facsimile or other electronic method of transmission shall be equally as effective as delivery of an original executed counterpart of this Agreement. Any party delivering an executed counterpart of this Agreement by facsimile or other electronic method of transmission also shall deliver an original executed counterpart of this Agreement but the failure to deliver an original executed counterpart shall not affect the validity, enforceability, and binding effect of this Agreement.

6. Successors and Assigns. This Agreement will be binding on and shall inure to the benefit of the parties hereto and their respective successors and assigns.

7. Governing Law.

(a) THE VALIDITY OF THIS AGREEMENT AND THE CONSTRUCTION, INTERPRETATION, AND ENFORCEMENT HEREOF, AND THE RIGHTS OF THE PARTIES HERETO WITH RESPECT TO ALL MATTERS ARISING HEREUNDER OR RELATED HERETO SHALL BE DETERMINED UNDER, GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK.

(b) THE PARTIES AGREE THAT ALL ACTIONS OR PROCEEDINGS ARISING IN CONNECTION WITH THIS AGREEMENT SHALL BE TRIED AND LITIGATED ONLY IN THE BANKRUPTCY COURT AND, TO THE EXTENT PERMITTED BY APPLICABLE LAW, FEDERAL COURTS LOCATED IN NEW YORK; PROVIDED, HOWEVER, THAT ANY SUIT SEEKING ENFORCEMENT AGAINST ANY COLLATERAL OR OTHER PROPERTY MAY BE BROUGHT, AT THE LENDER’S

OPTION, IN THE COURTS OF ANY JURISDICTION WHERE THE LENDER OR SUCH LENDER ELECTS TO BRING SUCH ACTION OR WHERE SUCH COLLATERAL OR OTHER PROPERTY MAY BE FOUND. THE GRANTORS AND THE LENDER WAIVE, TO THE EXTENT PERMITTED UNDER APPLICABLE LAW, ANY RIGHT EACH MAY HAVE TO ASSERT THE DOCTRINE OF *FORUM NON CONVENIENS* OR TO OBJECT TO VENUE TO THE EXTENT ANY PROCEEDING IS BROUGHT IN ACCORDANCE WITH THIS SECTION 7; PROVIDED, FURTHER, HOWEVER, THAT ALL PARTIES HEREBY AGREE THAT THEY HAVE CONSENTED TO THE JURISDICTION OF THE BANKRUPTCY COURT AND THAT THE BANKRUPTCY COURT WILL RETAIN EXCLUSIVE JURISDICTION WITH RESPECT TO ALL DISPUTES SO LONG AS THE CHAPTER 11 CASES REMAIN PENDING

**[Balance of Page Intentionally Left Blank]**

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTORS

SORRENTO THERAPEUTICS, INC.

By:   
Name: Mohsin Y. Meghji  
Title: Chief Restructuring Officer

Address:

4955 Directors Place  
San Diego, CA 92121  
ATTN: Mohsin Y. Meghji  
Chief Restructuring Officer

SCINTILLA PHARMACEUTICALS, INC.

By:   
Name: Mohsin Y. Meghji  
Title: Chief Restructuring Officer

Address:

4955 Directors Place  
San Diego, CA 92121  
ATTN: Mohsin Y. Meghji  
Chief Restructuring Officer

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

LENDER

Address:

**SCILEX HOLDING COMPANY**

960 San Antonio Rd.  
Palo Alto, CA 94303  
ATTN: Stephen Ma  
[sma@scilexholding.com](mailto:sma@scilexholding.com)

DocuSigned by:


By:   
Name: Stephen Ma  
Title: Chief Accounting Officer

EXHIBIT A

## Patents

	Patent Title	Application Number	Application Date	Patent Number	Grant Date	Status	Owner
1.	Application device for a fluid delivery apparatus and method of use	16469377	2019-06-13	11577023	2023-02-14	Issued	Sorrento Therapeutics Inc.
2.	Device for delivery of rheumatoid arthritis medication	16896941	2020-06-09	11565098	2023-01-31	Issued	Sorrento Therapeutics Inc.
3.	Fluid delivery apparatus and method of assembly	16799907	2020-02-25	11559674	2023-01-24	Issued	Sorrento Therapeutics Inc.
4.	Fluid delivery apparatus having a controller assembly and method of use	16469408	2019-06-13	11344709	2022-05-31	Issued	Sorrento Therapeutics Inc.
5.	Microneedle array assembly and fluid delivery apparatus having such an assembly	16095226	2018-10-19	11311708	2022-04-26	Issued	Sorrento Therapeutics Inc.
6.	Antigen binding proteins that bind WISPI	16374731	2019-04-03	11318202	2022-05-03	Issued	Sorrento Therapeutics Inc.
7.	Chemically-locked bispecific antibodies	16388760	2019-04-18	11267905	2022-03-08	Issued	Sorrento Therapeutics Inc.
8.	Transdermal drug delivery apparatus and methods	16261095	2019-01-29	11247033	2022-02-15	Issued	Sorrento Therapeutics Inc.
9.	Formulation of Resiniferatoxin	17569340	2022-01-05	---	---	Pending	Sorrento Therapeutics Inc.
10.	Fluid delivery apparatus having a controller assembly and method of use	17737270	2022-05-05	---	---	Pending	Sorrento Therapeutics Inc.
11.	Heterodimeric Antibodies That Bind to CD38 and CD3	17622087	2021-12-22	---	---	Pending	Sorrento Therapeutics Inc.
12.	Chemically-locked bispecific antibodies	17585378	2022-01-26	---	---	Pending	Sorrento Therapeutics Inc.
13.	Method for Treating Osteoarthritis Pain by Administering Resiniferatoxin	17424634	2021-07-21	---	---	Pending	Sorrento Therapeutics Inc.



	Patent Title	Application Number	Application Date	Patent Number	Grant Date	Status	Owner
14.	Transdermal drug delivery apparatus and methods	17563234	2021-12-28	---	---	Pending	Sorrento Therapeutics Inc.
15.	Activatable multi-specific antigen binding protein complexes	17602908	2021-10-11	---	---	Pending	Sorrento Therapeutics Inc.
16.	Dimeric Antigen Receptors (DAR) that Bind BCMA	17686261	2022-03-03	---	---	Pending	Sorrento Therapeutics Inc.
17.	Microneedle array assembly and fluid delivery apparatus having such an assembly	17699708	2022-03-21	---	---	Pending	Sorrento Therapeutics Inc.
18.	Cannabidiol Pharmaceutical Compositions	17601357	2021-10-04	---	---	Pending	Sorrento Therapeutics Inc.
19.	Improved process for dna integration using rna-guided endonucleases	17434209	2021-08-26	---	---	Pending	Sorrento Therapeutics Inc.
20.	Engineered Variant Antibodies that Bind CD38	17599377	2021-09-28	---	---	Pending	Sorrento Therapeutics Inc.
21.	Improved process for integration of dna constructs using rna-guided endonucleases	17438039	2021-09-10	---	---	Pending	Sorrento Therapeutics Inc.
22.	CD38 antibody drug conjugate	17518375	2021-11-03	---	---	Pending	Sorrento Therapeutics Inc.
23.	Method for administering a medicament suitable for treating a migraine or cluster headache	17538838	2021-11-30	---	---	Pending	Sorrento Therapeutics Inc.
24.	Implantable devices for delivery of bioactive agents	17391602	2021-08-02	---	---	Pending	Sorrento Therapeutics Inc.
25.	Small molecule c-Myc inhibitors	15035842	2016-05-11	11066398	2021-07-20	Issued	Sorrento Therapeutics Inc.  (Jointly owned with and licensed to NIH by The Scripps Research Institute)

Exhibit A-2

**TRADEMARK**  
**REEL: 008150 FRAME: 0458**

Patent Title	Application Number	Application Date	Patent Number	Grant Date	Status	Owner	
26.	Antigen binding proteins that bind CCR2	15097955	2016-04-13	9951138	2018-04-24	Issued	Sorrento Therapeutics Inc.
27.	Antibody therapeutics that bind JAG1	15063006	2016-03-07	10435476	2019-10-08	Issued	Sorrento Therapeutics Inc.
28.	Antibody therapeutics that bind CD47	15061771	2016-03-04	10035855	2018-07-31	Issued	Sorrento Therapeutics Inc.
29.	Antibody therapeutics that bind TIM3	15061832	2016-03-04	9873741	2018-01-23	Issued	Sorrento Therapeutics Inc.
30.	CD38 antibody drug conjugate	16013828	2018-06-20	11191845	2021-12-07	Issued	Sorrento Therapeutics Inc.
31.	Device for delivery of rheumatoid arthritis medication	16040714	2018-07-20	10709884	2020-07-14	Issued	Sorrento Therapeutics Inc.
32.	Antibody therapeutics that bind CD123	16135886	2018-09-19	10934361	2021-03-02	Issued	Sorrento Therapeutics Inc.
33.	Methods for better delivery of active agents to tumors	15744346	2018-01-12	10806913	2020-10-20	Issued	Sorrento Therapeutics Inc.
34.	Increased bioavailability of transdermally delivered agents	15890570	2018-02-07	10773065	2020-09-15	Issued	Sorrento Therapeutics Inc.
35.	Transdermal drug delivery device	14762844	2015-07-23	10183156	2019-01-22	Issued	Sorrento Therapeutics Inc.
36.	Anti-infective binding proteins that bind AIP2	15462427	2017-03-17	10472413	2019-11-12	Issued	Sorrento Therapeutics Inc.
37.	Antigen binding proteins that bind CCR2	13924501	2013-06-21	9315579	2016-04-19	Issued	Sorrento Therapeutics Inc.
38.	Drug delivery device	14762534	2015-07-22	9861801	2018-01-09	Issued	Sorrento Therapeutics Inc.
39.	Cartridge portion of transdermal drug delivery apparatus and methods	16170882	2018-10-25	10940085	2021-03-09	Issued	Sorrento Therapeutics Inc.

Exhibit A-3

**TRADEMARK**  
**REEL: 008150 FRAME: 0459**

	Patent Title	Application Number	Application Date	Patent Number	Grant Date	Status	Owner
40.	Antibody therapeutics that bind CD147	15304358	2016-10-14	10301386	2019-05-28	Issued	Sorrento Therapeutics Inc.
41.	Composite microneedle array including nanostructures thereon	16040892	2018-07-20	10806914	2020-10-20	Issued	Sorrento Therapeutics Inc.
42.	Variant antibodies that bind AIP2	16228570	2018-12-20	10774135	2020-09-15	Issued	Sorrento Therapeutics Inc.
43.	Method for administering a medicament suitable for treating a migraine or cluster headache	16469799	2019-06-14	11213666	2022-01-04	Issued	Sorrento Therapeutics Inc.
44.	Cartridge portion of transdermal drug delivery apparatus and methods	14914306	2016-02-25	10111807	2018-10-30	Issued	Sorrento Therapeutics Inc.
45.	Antibody therapeutics that bind CD123	15093777	2016-04-08	10100118	2018-10-16	Issued	Sorrento Therapeutics Inc.
46.	Antigen binding proteins that bind CCR2	15925494	2018-03-19	10696746	2020-06-30	Issued	Sorrento Therapeutics Inc.
47.	Antigen binding proteins that bind PD-L1	16111995	2018-08-24	11027012	2021-06-08	Issued	Sorrento Therapeutics Inc.
48.	Antibody therapeutics that bind CD38	16055065	2018-08-04	10800852	2020-10-13	Issued	Sorrento Therapeutics Inc.
49.	Fully human antibodies that bind to vascular endothelial growth factor receptor 2 (VEGFR2)	14680865	2015-04-07	11111304	2021-09-07	Issued	Sorrento Therapeutics Inc.
50.	Chemically-locked bispecific antibodies	15353979	2016-11-17	10301395	2019-05-28	Issued	Sorrento Therapeutics Inc.
51.	Medical devices for delivery of siRNA	13641502	2013-02-22	9522262	2016-12-20	Issued	Sorrento Therapeutics Inc.
52.	Injection molded microneedle array and method for forming the microneedle array	13641507	2013-02-22	9545507	2017-01-17	Issued	Sorrento Therapeutics Inc.

Exhibit A-4

**TRADEMARK**  
**REEL: 008150 FRAME: 0460**

	Patent Title	Application Number	Application Date	Patent Number	Grant Date	Status	Owner
53.	Composite microneedle array including nanostructures thereon	13641504	2013-02-22	9526883	2016-12-27	Issued	Sorrento Therapeutics Inc.
54.	Methods for lymphatic delivery of active agents	16925548	2020-07-10	---	---	Pending	Sorrento Therapeutics Inc.
55.	Medical devices for delivery of siRNA	16040773	2018-07-20	11135414	2021-10-05	Issued	Sorrento Therapeutics Inc.
56.	Nanopatterned medical device with enhanced cellular interaction	13095489	2011-04-27	10245421	2019-04-02	Issued	Sorrento Therapeutics Inc.
57.	Antibody therapeutics that bind CD137	15050215	2016-02-22	10259881	2019-04-16	Issued	Sorrento Therapeutics Inc.
58.	Antigen binding proteins that bind WISPI	15330956	2015-04-14	10272154	2019-04-30	Issued	Sorrento Therapeutics Inc.
59.	Process for dna integration using ma-guided endonucleases	16288052	2019-02-27	---	---	Pending	Sorrento Therapeutics Inc.
60.	Transdermal delivery of high viscosity bioactive agents	14354229	2014-04-25	9550053	2017-01-24	Issued	Sorrento Therapeutics Inc.
61.	Antibody therapeutics that bind STAT3	15496994	2017-04-25	10233255	2019-03-19	Issued	Sorrento Therapeutics Inc.
62.	Attachment band for a fluid delivery apparatus and method of use	16469061	2019-06-12	11219721	2022-01-11	Issued	Sorrento Therapeutics Inc.
63.	Microneedle array assembly, drug delivery device and method for administering liquid across a broad area at low pressure	16095210	2018-10-19	11179554	2021-11-23	Issued	Sorrento Therapeutics Inc.
64.	Antibody therapeutics that bind CD137	16270761	2019-02-08	11180568	2021-11-23	Issued	Sorrento Therapeutics Inc.
65.	Nanopatterned medical device with enhanced cellular interaction	16361484	2019-03-22	11179555	2021-11-23	Issued	Sorrento Therapeutics Inc.

Exhibit A-5

**TRADEMARK**  
**REEL: 008150 FRAME: 0461**

	Patent Title	Application Number	Application Date	Patent Number	Grant Date	Status	Owner
66.	Drug-conjugates with a targeting molecule and two different drugs	14515352	2014-10-15	10836821	2020-11-17	Issued	Sorrento Therapeutics Inc.
67.	Fluid delivery apparatus having a gas extraction device and method of use	16469035	2019-06-12	10569010	2020-02-25	Issued	Sorrento Therapeutics Inc.
68.	Cell penetrating peptide inhibitors of p53-MDM2 interaction	15880101	2018-01-25	10583193	2020-03-10	Issued	Sorrento Therapeutics Inc.
69.	Antibody drug conjugates	15009775	2016-01-28	10590165	2020-03-17	Issued	Sorrento Therapeutics Inc.
70.	Anti-infective binding proteins that bind AIP2	14062774	2013-10-24	8859740	2014-10-14	Issued	Sorrento Therapeutics Inc.
71.	Methods for treating subjects having a CXC chemokine receptor 5 (CXCR5)-responsive cancer by administering fully human anti-CXCR5 antibodies	15674401	2017-08-10	10479837	2019-11-19	Issued	Sorrento Therapeutics Inc.
72.	Method for increasing the permeability of an epithelial barrier	13641500	2013-02-22	9586044	2017-03-07	Issued	Sorrento Therapeutics Inc.
73.	Antibody therapeutics that bind CD38	15094384	2016-04-08	10059774	2018-08-28	Issued	Sorrento Therapeutics Inc.
74.	Antigen binding proteins that bind PD-L1	15619389	2017-06-09	10058609	2018-08-28	Issued	Sorrento Therapeutics Inc.
75.	Device for delivery of rheumatoid arthritis medication	13641501	2013-02-22	9522263	2016-12-20	Issued	Sorrento Therapeutics Inc.
76.	Draped microneedle array	14914302	2016-02-25	9962536	2018-05-08	Issued	Sorrento Therapeutics Inc.
77.	Antibody therapeutics that bind CD38	15093773	2016-04-08	9951144	2018-04-24	Issued	Sorrento Therapeutics Inc.
78.	Antigen binding proteins that bind c-Met	16451511	2019-06-25	11155628	2021-10-26	Issued	Sorrento Therapeutics Inc.

Exhibit A-6

**TRADEMARK**  
**REEL: 008150 FRAME: 0462**

	Patent Title	Application Number	Application Date	Patent Number	Grant Date	Status	Owner
79.	Antibody therapeutics that bind CD123	15093780	2016-04-08	9969807	2018-05-15	Issued	Sorrento Therapeutics Inc.
80.	Antigen Binding Proteins that Bind EGFR	13893312	2013-05-13	9944707	2018-04-17	Issued	Sorrento Therapeutics Inc.
81.	Anti-infective binding proteins that bind AIP2	14473916	2014-08-29	9631009	2017-04-25	Issued	Sorrento Therapeutics Inc.
82.	Antigen binding proteins that bind PD-L1	13907685	2013-05-31	9175082	2015-11-03	Issued	Sorrento Therapeutics Inc.
83.	Cell internalizing compounds	16455184	2019-06-27	10925968	2021-02-23	Issued	Sorrento Therapeutics Inc.
84.	Antibody therapeutics that bind PSMA	15066806	2016-03-10	10100126	2018-10-16	Issued	Sorrento Therapeutics Inc.
85.	Antigen binding proteins that bind PD-L1	15418514	2017-01-27	10118963	2018-11-06	Issued	Sorrento Therapeutics Inc.
86.	Collet for a fluid delivery apparatus	29587922	2016-12-16	D831198	2018-10-16	Issued	Sorrento Therapeutics Inc.
87.	Transdermal patch containing microneedles	13036096	2011-02-28	8696637	2014-04-15	Issued	Sorrento Therapeutics Inc.
88.	Disulfide bridging conjugates	16052406	2018-08-01	10799598	2020-10-13	Issued	Sorrento Therapeutics Inc.
89.	Chemically-locked bispecific antibodies	15310214	2016-11-10	10435479	2019-10-08	Issued	Sorrento Therapeutics Inc.
90.	Antigen binding proteins that bind c-met	13924492	2013-06-21	10377827	2019-08-13	Issued	Sorrento Therapeutics Inc.
91.	Fluid delivery apparatus	29587924	2016-12-16	D819197	2018-05-29	Issued	Sorrento Therapeutics Inc.
92.	Dimeric Antigen Receptors	17013359	2020-09-04	---	---	Pending	Sorrento Therapeutics Inc.
93.	Anti-ox40 binding proteins	16995573	2020-08-17	---	---	Pending	Sorrento Therapeutics Inc.
94.	Increased bioavailability of transdermally delivered agents	16992776	2020-08-13	---	---	Pending	Sorrento Therapeutics Inc.

Exhibit A-7

**TRADEMARK**  
**REEL: 008150 FRAME: 0463**

Patent Title	Application Number	Application Date	Patent Number	Grant Date	Status	Owner
95. Method for increasing permeability of a cellular layer of epithelial cells	16422195	2019-05-24	11083881	2021-08-10	Issued	Sorrento Therapeutics Inc.
96. Anti-KRAS binding proteins	16380121	2019-04-10	11174314	2021-11-16	Issued	Sorrento Therapeutics Inc.
97. Fluid delivery apparatus having a gas extraction device and method of use	17130326	2020-12-22	11235101	2022-02-01	Issued	Sorrento Therapeutics Inc.
98. Variant antibody that binds CD38	17127766	2020-12-18	---	---	Pending	Sorrento Therapeutics Inc.
99. Anti-cancer phosphorothioate-coupled peptide conjugates and methods of using the same	16630347	2020-01-10	---	---	Pending	Sorrento Therapeutics Inc.  (Jointly owned with City of Hope)
100. Drug-Conjugates With a Targeting Molecule and Two Different Drugs	17037370	2020-09-29	---	---	Pending	Sorrento Therapeutics Inc.
101. Antibody therapeutics that bind CD123	17150884	2021-01-15	---	---	Pending	Sorrento Therapeutics Inc.
102. Drug delivery methods targeting the lymphatic system	15733817	2020-11-30	---	---	Pending	Sorrento Therapeutics Inc.
103. Intracellular delivery compounds	15298813	2016-10-20	10336829	2019-07-02	Issued	Sorrento Therapeutics Inc.
104. Fully human antibodies that bind to VEGFR2	13854071	2013-03-30	9029510	2015-05-12	Issued	Sorrento Therapeutics Inc.
105. Cartridge portion of transdermal drug delivery apparatus and methods	17166391	2021-02-03	---	---	Pending	Sorrento Therapeutics Inc.
106. Methods for better delivery of active agents to tumors	17022855	2020-09-16	---	---	Pending	Sorrento Therapeutics Inc.
107. Disulfide bridging conjugates	17008432	2020-08-31	---	---	Pending	Sorrento Therapeutics Inc.
108. Antibody therapeutics that bind TIM3	15842161	2017-12-14	10927171	2021-02-23	Issued	Sorrento Therapeutics Inc.

	Patent Title	Application Number	Application Date	Patent Number	Grant Date	Status	Owner
109	Anti-OX40 binding proteins	16323968	2019-02-07	10781260	2020-09-22	Issued	Sorrento Therapeutics Inc.
110	Antibody therapeutics that bind CTLA4	16243016	2019-01-08	11155623	2021-10-26	Issued	Sorrento Therapeutics Inc.
111	Antibody drug conjugates having derivatives of amatoxin as the drug	15609858	2017-05-31	11013816	2021-05-25	Issued	Sorrento Therapeutics Inc.
112	Transdermal delivery of high viscosity bioactive agents	16244914	2019-01-10	11129975	2021-09-28	Issued	Sorrento Therapeutics Inc.
113	Variant antibodies that bind OX40	16212349	2018-12-06	11142579	2021-10-12	Issued	Sorrento Therapeutics Inc.
114	Implantable devices for delivery of bioactive agents	14354223	2014-04-25	11110066	2021-09-07	Issued	Sorrento Therapeutics Inc.
115	Receptacle portion of transdermal drug delivery apparatus and methods	15305206	2016-10-19	11040183	2021-06-22	Issued	Sorrento Therapeutics Inc.
116	Transdermal drug delivery device	16224249	2018-12-18	10953211	2021-03-23	Issued	Sorrento Therapeutics Inc.
117	Transdermal device containing microneedles	13157412	2011-06-10	8636696	2014-01-28	Issued	Sorrento Therapeutics Inc.
118	Antigen binding proteins that bind ErbB3	14061548	2013-10-23	9346890	2016-05-24	Issued	Sorrento Therapeutics Inc.
119	Methods for lymphatic delivery of active agents	15744385	2018-01-12	10737082	2020-08-11	Issued	Sorrento Therapeutics Inc.
120	Fluid delivery apparatus having a gas extraction device and method of use	16738390	2020-01-09	10905822	2021-02-02	Issued	Sorrento Therapeutics Inc.
121	Fluid delivery apparatus and method of assembly	16469353	2019-06-13	10603478	2020-03-31	Issued	Sorrento Therapeutics Inc.
122	Antigen binding proteins that bind ErbB3	15141593	2016-04-28	9938352	2018-04-10	Issued	Sorrento Therapeutics Inc.
123	Antibody therapeutics that bind OprF and	14839791	2015-08-28	9879069	2018-01-30	Issued	Sorrento Therapeutics Inc.

Exhibit A-9

**TRADEMARK**  
**REEL: 008150 FRAME: 0465**



	Patent Title	Application Number	Application Date	Patent Number	Grant Date	Status	Owner
	Oprl						
124	Composite microneedle array including nanostructures thereon	15382774	2016-12-19	10029084	2018-07-24	Issued	Sorrento Therapeutics Inc.
125	Transdermal drug delivery apparatus and methods	15305193	2016-10-19	10232160	2019-03-19	Issued	Sorrento Therapeutics Inc.
126	Method for increasing the permeability of an epithelial barrier	15413475	2017-01-24	10342965	2019-07-09	Issued	Sorrento Therapeutics Inc.
127	Transdermal delivery of high viscosity bioactive agents	15411318	2017-01-20	10213588	2019-02-26	Issued	Sorrento Therapeutics Inc.
128	Cartridge for a fluid delivery apparatus	29587923	2016-12-16	D836774	2018-12-25	Issued	Sorrento Therapeutics Inc.
129	Device for delivery of rheumatoid arthritis medication	15378097	2016-12-14	10029082	2018-07-24	Issued	Sorrento Therapeutics Inc.
130	Medical devices for delivery of siRNA	15378109	2016-12-14	10029083	2018-07-24	Issued	Sorrento Therapeutics Inc.
131	Antigen binding proteins that bind PD-L1	16156895	2018-10-10	10919964	2021-02-16	Issued	Sorrento Therapeutics Inc.
132	Microneedles with improved open channel cross-sectional geometries	14787044	2015-10-26	9795775	2017-10-24	Issued	Sorrento Therapeutics Inc.
133	Antibody therapeutics that bind LAG3	15217238	2016-07-22	9902772	2018-02-27	Issued	Sorrento Therapeutics Inc.
134	Applicator device for a fluid delivery apparatus	29587926	2016-12-16	D810927	2018-02-20	Issued	Sorrento Therapeutics Inc.
135	Strap component for a fluid delivery apparatus	29587921	2016-12-16	D810604	2018-02-20	Issued	Sorrento Therapeutics Inc.
136	Carrying case	29587927	2016-12-16	D810421	2018-02-20	Issued	Sorrento Therapeutics Inc.
137	Antibody therapeutics that bind CTLA4	15043157	2016-02-12	10202453	2019-02-12	Issued	Sorrento Therapeutics Inc.

Exhibit A-10

**TRADEMARK**  
**REEL: 008150 FRAME: 0466**

	Patent Title	Application Number	Application Date	Patent Number	Grant Date	Status	Owner
138	Controller portion of transdermal drug delivery apparatus and methods	15305201	2016-10-19	10328248	2019-06-25	Issued	Sorrento Therapeutics Inc.
139	Antibody therapeutics that bind CD137	15049718	2016-02-22	10233251	2019-03-19	Issued	Sorrento Therapeutics Inc.
140	Antigen binding proteins that bind PD-L1	17306395	2021-05-03	---	---	Pending	Sorrento Therapeutics Inc.
141	Antigen Binding Proteins that Bind BCMA	17412089	2021-08-25	---	---	Pending	Sorrento Therapeutics Inc.
142	Methods for Treating Parkinson'S Disease by Administering Resiniferatoxin	17345641	2021-06-11	---	---	Pending	Sorrento Therapeutics Inc.
143	Antigen Binding Proteins that Bind PD-L1	17148450	2021-01-13	---	---	Pending	Sorrento Therapeutics Inc.
144	Antibody Drug Conjugates Having Derivatives of Amatoxin As The Drug	17240700	2021-04-26	---	---	Pending	Sorrento Therapeutics Inc.
145	Transdermal drug delivery device	17178817	2021-02-18	---	---	Pending	Sorrento Therapeutics Inc.
146	Compositions and Methods Comprising an Anti-CD47 Antibody in Combination with a Tumor Targeting Antibody	17112587	2020-12-04	---	---	Pending	Sorrento Therapeutics Inc.
147	Antigen Binding Proteins that Bind c-Met	17482140	2021-09-22	---	---	Pending	Sorrento Therapeutics Inc.
148	MEDICAL DEVICES FOR DELIVERY OF siRNA	17464402	2021-09-01	---	---	Pending	Sorrento Therapeutics Inc.
149	Variant antibodies that bind OX40	17409595	2021-08-23	---	---	Pending	Sorrento Therapeutics Inc.
150	Antibody Therapeutics that Bind CTLA4	17482138	2021-09-22	---	---	Pending	Sorrento Therapeutics Inc.
151	Perineural Administration of	17345545	2021-06-11	---	---	Pending	Sorrento Therapeutics Inc.

Exhibit A-11

	Patent Title	Application Number	Application Date	Patent Number	Grant Date	Status	Owner
	Resiniferatoxin for Treatment of Maladaptive Pain						
152	Transdermal delivery of high viscosity bioactive agents	17408699	2021-08-23	---	---	Pending	Sorrento Therapeutics Inc.
153	Antibody therapeutics that bind CD137	17499127	2021-10-12	---	---	Pending	Sorrento Therapeutics Inc.
154	Fully Human Antibodies That Bind to Vascular Endothelial Growth Factor Receptor (VEGFR2)	17389181	2021-07-29	---	---	Pending	Sorrento Therapeutics Inc.
155	Microneedle array assembly, drug delivery device and method for administering liquid across a broad area at low pressure	17509182	2021-10-25	---	---	Pending	Sorrento Therapeutics Inc.
156	Nanopatterned medical device with enhanced cellular interaction	17504718	2021-10-19	---	---	Pending	Sorrento Therapeutics Inc.
157	Antibody Therapeutics that Bind CD38	17016104	2020-09-09	---	---	Pending	Sorrento Therapeutics Inc.
158	Composite microneedle array including nanostructures thereon	17029229	2020-09-23	---	---	Pending	Sorrento Therapeutics Inc.
159	CD-38 directed chimeric antigen receptor constructs	16179850	2018-11-02	---	---	Pending	Sorrento Therapeutics Inc.
160	Antigen binding proteins that bind PD-1	16742712	2020-01-14	11242391	2022-02-08	Issued	Sorrento Therapeutics Inc.
161	Antigen Binding Proteins that Bind PD-1	17554926	2021-12-17	---	---	Pending	Sorrento Therapeutics Inc.
162	Methods for blocking an interaction between notch-1 and delta-like 4 (DLL-4) by administering a DLL-4 antibody	16241828	2019-01-07	10717779	2020-07-21	Issued	Sorrento Therapeutics Inc.

Exhibit A-12

	Patent Title	Application Number	Application Date	Patent Number	Grant Date	Status	Owner
163.	Antibodies which bind insulin-like growth factor receptor-1 (IGF1R) and methods of use thereof to treat cancer	13916129	2013-06-12	10519245	2019-12-31	Issued	Sorrento Therapeutics Inc.
164.	Antigen binding proteins that bind PD-1	14292866	2014-05-31	9676853	2017-06-13	Issued	Sorrento Therapeutics Inc.
165.	Antigen binding proteins that bind PD-1	15589051	2017-05-08	10584168	2020-03-10	Issued	Sorrento Therapeutics Inc.
166.	Method of treating cancer by administration of an anti-PD-1 or anti-PD-L1 therapeutic agent via a lymphatic delivery device	17781672	2022-06-01	---	---	Pending	Sorrento Therapeutics Inc.
167.	Antigen binding proteins that bind delta-like 4 (DLL-4)	13903793	2013-05-28	10174107	2019-01-08	Issued	Sorrento Therapeutics Inc.
168.	Antigen Binding Proteins that Bind CXCR3	14821559	2015-08-07	9765145	2017-09-19	Issued	Sorrento Therapeutics Inc.
169.	Fully human anti-C-X-C chemokine receptor 3 (CXCR3) antibodies and methods of use thereof	16155278	2018-10-09	10668148	2020-06-02	Issued	Sorrento Therapeutics Inc.
170.	Fully human anti-CXC chemokine receptor 5 (CXCR5) antibodies	14825144	2015-08-12	9765146	2017-09-19	Issued	Sorrento Therapeutics Inc.

EXHIBIT B

**Trademarks**

	<b>Trademark</b>	<b>Application Number Application Date</b>	<b>Registration Number Registration Date</b>	<b>Status</b>	<b>Owner</b>
1.	DOSECONNECT	87218765 28-OCT-2016	5429288 20-MAR-2018	Registered	Sorrento Therapeutics, Inc.
2.	DOSECONNECT	87218763 28-OCT-2016	5449373 17-APR-2018	Registered	Sorrento Therapeutics, Inc.
3.	DOSEDISC	86420150 10-OCT-2014	5459332 01-MAY-2018	Registered	Sorrento Therapeutics, Inc.
4.	SOFUSA  SOFUSA	86420148 10-OCT-2014	5448790 17-APR-2018	Registered	Sorrento Therapeutics, Inc.
5.	SOFUSA  SOFUSA	86420149 10-OCT-2014	5428688 20-MAR-2018	Registered	Sorrento Therapeutics, Inc.
6.	SORRENTO  SORRENTO	86639376 22-MAY-2015	5800560 09-JUL-2019	Registered	Sorrento Therapeutics, Inc.
7.	SORRENTO  sorrento	86639383 22-MAY-2015	5800561 09-JUL-2019	Registered	Sorrento Therapeutics, Inc.

EXHIBIT C

**Copyrights**

None

Exhibit C